We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Experimental Drug May Be Universal Cure for Kinetoplastid-Based Diseases

By LabMedica International staff writers
Posted on 17 Aug 2016
An experimental drug that targets the kinetoplast proteasome found in several types of protozoan parasites shows potential for development into a universal treatment for these pathogenic microorganisms.

Chagas disease, leishmaniasis, and sleeping sickness affect some 20 million people worldwide and lead to more than 50,000 deaths annually. More...
The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei spp., respectively. These parasites have similar biology and genomic sequence, suggesting that all three diseases could be cured by treatment to block the activity of a conserved parasite target. However, no such molecular targets or broad-spectrum drugs have been identified to date.

A significant advance in the search for a drug to treat kinetoplastid parasite infections was described in the August 8, 2016, online edition of the journal Nature. Investigators from several British research institutes in collaboration with the Novartis Research Foundation (San Diego, CA, USA) and the Wellcome Trust (United Kingdom) evaluated the experimental drug GNF6702, which had been discovered during a screen of more than three million compounds by the Genomics Institute of the Novartis Research Institute.

The investigators reported that GNF6702 demonstrated unprecedented in vivo efficacy by clearing parasites from mice in all three models of infection. GNF6702 inhibited the kinetoplastid proteasome through a non-competitive mechanism, did not inhibit the mammalian proteasome or growth of mammalian cells, and was well tolerated in mice.

Senior author Dr. Frantisek Supek, a biotechnology researcher at the Novartis Research Foundation, said, "We found that these parasites harbor a common weakness. We hope to exploit this weakness to discover and develop a single class of drugs for all three diseases."

Dr. Stephen Caddick, director of innovation at the Wellcome Trust, said, "These three diseases lead to more than 50,000 deaths annually, yet they receive relatively little funding for research and drug development. We hope that our early stage support for this research will provide a basis for the development of new treatments that could reduce suffering for millions of people in the poorest regions of the world."

Related Links:
Novartis Research Foundation
Wellcome Trust

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.